Abera is a Swedish biotech company headquartered in Stockholm, Sweden. Abera is committed to becoming a world-leading company in innovative vaccine technologies.

MANAGEMENT TEAM

Joen Luirink

CSO, Member of the Board

Prof. Luirink has more than 25 years of experience in Biochemistry and Molecular Microbiology and authored over 130 original scientific publications in peer-reviewed journals. Prof. Luirink specializes in protein trafficking in bacteria. He is currently head of the Department of Molecular Microbiology at VU University Amsterdam, and serves as the CSO of Abera.

Anders Ericson

Chairman of the Board, Acting CEO

Anders Ericson has worked in several positions within the financial industry for more than 18 years. He is the owner and CEO of Smallcap.se, which is a financial communications firm specializing in life science companies.

BOARD OF DIRECTORS

Anders Ericson

Chairman of the Board, Acting CEO

Anders Ericson has worked in several positions within the financial industry for more than 18 years. He is the owner and CEO of Smallcap.se, which is a financial communications firm specializing in life science companies.

Alf Lindberg

Member of the Board

Prof. Alf Lindberg has held the CSO position and Director of R&D position at Wyeth Vaccines and Sanofi Pasteur. He has extensive experience in vaccine development and is also a former professor in Clinical Bacteriology at Karolinska Institute in Stockholm. Prof. Lindberg is active as board member in several biotech and vaccine development companies worldwide.

Joen Luirink

CSO, Member of the Board

Prof. Luirink has more than 25 years of experience in Biochemistry and Molecular Microbiology and authored over 130 original scientific publications in peer-reviewed journals. Prof. Luirink specializes in protein trafficking in bacteria. He is currently head of the Department of Molecular Microbiology at VU University Amsterdam, and serves as the CSO of Abera.

Jens Holmberg

Member of the Board

Dr. Holmberg currently holds the CSO position at the publicly-held medtech company SensoDetect where he also served as CEO during 2012-2014. He has held key positions in various biotech companies where he has directed successful proof of concept studies leading to several patents considering vaccine design and novel adjuvants. Holmberg holds a PhD in Immunology, an MSc in Biomedicine and an MSc in Chemistry with studies from University of Cambridge, USC Medical School Los Angeles and University of Lund.